The cannabinoid diagnostics company finds encouraging antitumor THC and THCA activity
TEL AVIV, Israel and BETHESDA, Maryland, March 29, 2018 /PRNewswire/ --
Cannabics Pharmaceuticals Inc. (CNBX), a leader in cannabinoid diagnostic tests for personalized cancer therapy, today announced encouraging results from a preclinical study on the antitumor effects of cannabinoids on cancerous tumor cells.
The study indicates that cancer cells derived from patient blood samples are differentially sensitive to the main active compounds in cannabis, tetrahydrocannabinol (THC) and tetrahydrocannabinolic acid (THCA). Circulating tumor cells - cancer cells that detach from a primary tumor and circulate through the bloodstream - were isolated from blood samples of breast cancer and prostate cancer patients and treated with either THC or THCA. Cell viability was monitored over time.
The results indicate that the cannabinoid compounds have different apoptotic - or cell-killing effects - depending on the dosage, type of cancer and the compound configuration.
Dr. Eyal Ballan, Cannabics co-founder and chief technology officer, said "The results of this latest study further validate Cannabics' ability to perform cannabinoid sensitivity tests on liquid biopsies and indicate in vitro antitumor activity of these compounds, which should be further examined in clinical studies. While the current use of medical cannabis is largely used for palliative purposes when it comes to cancer, we are seeing a growing number of clinical studies on the antitumor effects of cannabinoids and predict we will start to see eventual FDA approvals of cannabinoids to treat various types of cancer. Our goal is to support the personalization of these treatments with our drug sensitivity and therapy monitoring tests."
Cannabics conducts high-throughput screenings to detect correlations between cannabinoid dosages and anti-tumor activity using a growing library of human cancer cell lines and different types and ratios of active cannabinoid compounds. These novel screening technologies are expected to offer valuable databases to help medical professionals make the most effective treatment decisions for their patients.
About Cannabics Pharmaceuticals
Cannabics Pharmaceuticals Inc. (CNBX) is a US based public company with a R&D division based in Israel, where it is fully licensed by the Ministry of Health for its work in both scientific and clinical research. Cannabics is now developing cannabinoid diagnostic tests for the personalized treatment of cancer. Cannabics is developing a blood test designed to allow practitioners to precisely tailor medical cannabinoid-based therapies to an individual patient's profile and cancer. Cannabics' approach can also be used to develop cannabinoid-based therapies as preventive or primary cancer treatments - not just palliative. By developing tools to assess effectiveness on a personalized basis, Cannabics is moving medical cannabinoids into the mainstream of anti-cancer science.
Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on January 16th, 2018. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.
Finally, the investing public is reminded that the only announcements or information about Cannabics Pharmaceuticals Inc. which are condoned by the Company must emanate from the Company itself and bear our name as its Source.
For further information, please contact: